Research programme: sensorineural hearing loss therapeutics - Oricula Therapeutics

Drug Profile

Research programme: sensorineural hearing loss therapeutics - Oricula Therapeutics

Alternative Names: ORC-0001; ORC-13661; OT-0001

Latest Information Update: 08 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Washington
  • Developer Oricula Therapeutics
  • Class
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sensorineural hearing loss

Most Recent Events

  • 02 Feb 2016 Oricula Therapeutics receives Small Business Innovation Research Program grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for development of ORC 13661
  • 02 Feb 2016 Pharmacodynamics data from preclinical studies in Sensorineural hearing loss released by Oricula Therapeutics
  • 30 Apr 2014 Oricula Therapeutics receives Small Business Innovation Research Program grant from the National Institutes of Health for Sensorineural hearing loss programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top